{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:35:09Z","timestamp":1793061309221,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xcrm.2026.102931","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:14:53Z","timestamp":1784733293000},"page":"102931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial"],"prefix":"10.1016","volume":"7","author":[{"given":"Liang","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-7176","authenticated-orcid":false,"given":"Yongchang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102931_bib1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The Effect of Advances in Lung-Cancer Treatment on Population Mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102931_bib2","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41586-024-07177-7","article-title":"Evolutionary trajectories of small cell lung cancer under therapy","volume":"627","author":"George","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102931_bib3","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3389\/fonc.2020.01074","article-title":"Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)","volume":"10","author":"Saltos","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.102931_bib4","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1200\/JCO.2013.51.4109","article-title":"Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer","volume":"32","author":"Allen","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102931_bib5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1200\/JCO.2010.29.8851","article-title":"Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy","volume":"29","author":"Jotte","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102931_bib6","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","article-title":"Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer","volume":"32","author":"von Pawel","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102931_bib7","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study","volume":"38","author":"Rudin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102931_bib8","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","article-title":"Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies","volume":"15","author":"Chung","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2026.102931_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","article-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331(\u2606)","volume":"32","author":"Spigel","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102931_bib10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/cas.13536","article-title":"Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor","volume":"109","author":"Xie","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.xcrm.2026.102931_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.xcrm.2026.102931_bib12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1078-0432.CCR-21-2241","article-title":"Anlotinib Induces a T Cell-Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma","volume":"28","author":"Su","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102931_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41419-020-02749-7","article-title":"Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma","volume":"11","author":"Song","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2026.102931_bib14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41416-021-01356-3","article-title":"Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study","volume":"125","author":"Cheng","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102931_bib15","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1002\/cncr.34977","article-title":"Advancing immunotherapy in small cell lung cancer","volume":"129","author":"Carlisle","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2026.102931_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(23)00431-9","article-title":"First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial","volume":"12","author":"Zhong","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.xcrm.2026.102931_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.684867","article-title":"Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib\/II Trial (AK105-203)","volume":"11","author":"Han","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.102931_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102194","article-title":"Penpulimab combined with anlotinib in patients with R\/M HNSCC after failure of platinum-based chemotherapy: a single-arm, multicenter, phase \u2161 study","volume":"8","author":"Shi","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.xcrm.2026.102931_bib19","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102931_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41392-024-01857-6","article-title":"First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel\/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial","volume":"9","author":"Sha","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2026.102931_bib21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41577-025-01187-w","article-title":"Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy","volume":"25","author":"Lanitis","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.102931_bib22","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.21037\/tlcr-23-215","article-title":"Tarlatamab: a potential new option for recurrent small cell lung cancer","volume":"12","author":"Addeo","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102931_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41392-025-02153-7","article-title":"Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2026.102931_bib24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41392-023-01672-5","article-title":"Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer","volume":"8","author":"Han","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2026.102931_bib25","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00262-020-02642-4","article-title":"Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer","volume":"69","author":"Zhang","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2026.102931_bib26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3816\/CLC.2008.n.023","article-title":"A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer","volume":"9","author":"Jones","year":"2008","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.xcrm.2026.102931_bib27","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2023.4025","article-title":"Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial","volume":"9","author":"Takahashi","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102931_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.lungcan.2022.03.003","article-title":"Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer","volume":"166","author":"Edelman","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.xcrm.2026.102931_bib29","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1038\/s41598-024-54223-5","article-title":"A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer","volume":"14","author":"Cheng","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.102931_bib30","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jtho.2025.02.005","article-title":"Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I\/II LUPER Study","volume":"20","author":"Calles","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2026.102931_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102543","article-title":"Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial","volume":"70","author":"Ma","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.xcrm.2026.102931_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41392-024-01957-3","article-title":"Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial","volume":"9","author":"Han","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2026.102931_bib33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jtho.2020.10.002","article-title":"Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial","volume":"16","author":"Fan","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2026.102931_bib34","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102931_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225649","article-title":"Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer","volume":"14","author":"Dong","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102931_bib36","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1186\/s12885-022-09897-3","article-title":"Bias and inconsistency in the estimation of tumour mutation burden","volume":"22","author":"Makrooni","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xcrm.2026.102931_bib37","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41591-022-01754-x","article-title":"Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial","volume":"28","author":"Kim","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102931_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102606","article-title":"Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy","volume":"120","author":"Chen","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.xcrm.2026.102931_bib39","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1158\/1078-0432.CCR-19-2931","article-title":"Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102931_bib40","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.102931_bib41","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1126\/science.1121613","article-title":"Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock","volume":"311","author":"Yin","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102931_bib42","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nmeth.3364","article-title":"MiXCR: software for comprehensive adaptive immunity profiling","volume":"12","author":"Bolotin","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2026.102931_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006243","article-title":"Heterogeneity of tumor immune microenvironment of EGFR\/ALK-positive tumors versus EGFR\/ALK-negative tumors in resected brain metastases from lung adenocarcinoma","volume":"11","author":"Xiao","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102931_bib44","article-title":"Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102931_bib45","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.1158\/1078-0432.CCR-21-1537","article-title":"Genomic Landscape and Tumor Mutational Burden Determination of Circulating Tumor DNA in Over 5,000 Chinese Patients with Lung Cancer","volume":"27","author":"Shi","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102931_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/gpbjnl\/qzaf017","article-title":"Evaluative Methodology for HRD Testing: Development of Standard Tools for Consistency Assessment","volume":"23","author":"Jia","year":"2025","journal-title":"Genom. Proteom. Bioinform."},{"key":"10.1016\/j.xcrm.2026.102931_bib47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s40364-025-00843-6","article-title":"Comprehensive assessment of homologous recombination deficiency via simultaneous methylation and mutation analysis in epithelial ovarian cancer: implications for PARP inhibitors efficacy","volume":"13","author":"Dong","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.xcrm.2026.102931_bib48","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102931_bib49","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102931_bib50","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","article-title":"Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102931_bib51","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1038\/s41467-018-07767-w","article-title":"Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer","volume":"9","author":"Jia","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102931_bib52","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa452","article-title":"TCR-Seq Identifies Distinct Repertoires of Distant-Metastatic and Nondistant-Metastatic Thyroid Tumors","volume":"105","author":"Lan","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:23:07Z","timestamp":1793060587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126003484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666379126003484"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102931","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102931"}}